SCHEMBL4629422

SCHEMBL4629422

CC(C)c1ccc(NC(=N)NC(=O)c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RAB9A P51151 3/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 3/20 0.52
NPC1 O15118 2/20 0.52
PKM P14618 1/20 0.52
BCAT2 O15382 1/20 0.51
HPGD P15428 1/20 0.48
S1PR3 Q99500 4/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
TP53 P04637 1/20 0.46
PANK3 Q9H999 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628487 0.85 SMN1; SMN2 (0.52) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4628463 0.83 NPC1 (0.55) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4628446 0.82 SCN5A (0.54) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4629403 0.81 CRHBP (0.52) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4628729 0.81 TAS1R3 (0.49) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4628721 0.79 RAB9A (0.63) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4629293 0.78 ALDH1A1 (0.47) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4627470 0.77 ALDH1A1 (0.51) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4659371 0.77 HPGD (0.46) MEN1KMT2ARAB9AMAPTKDM4E
SCHEMBL4629439 0.75 JAK2 (0.49) MEN1KMT2ARAB9ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1032556-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE INC (US) 2005-02-02 EP claimed
EP-1032556-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-09-06 EP claimed
WO-1999020599-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-04-29 WO claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA MEN1 1819/4885KMT2A 3245/4885RAB9A 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.